55 completed. 55 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 55 | Completed 55 |
| Phase 2 | 12 | Completed 12 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Autoinjector - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 87 | 2025-07-01 | 2026-06-25 |
| Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery L-thyroxine, Placebo Oral Tablet - Cardiac Surgery Intensive Care Treatment, Delayed Recovery From Anaesthesia | Phase 3 | Completed | Ain Shams University | 70 | 2024-11-30 | 2025-08-17 |
| A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) Veligrotug - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 231 | 2024-05-23 | 2026-08-13 |
| Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism Vitamin D, Levothyroxin - Hypothyroidism Primary, Lipid Disorder | Phase 3 | Completed | King Edward Medical University | 62 | 2024-03-01 | 2025-03-11 |
| An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 Veligrotug - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 139 | 2024-01-31 | 2026-08-14 |
| A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy Placebo, IBI311 - Thyroid Associated Ophthalmopathy | Phase 3 | Completed | Peking University People's Hospital | 53 | 2024-01-01 | 2026-03-24 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Hoffmann-La Roche | 127 | 2023-11-15 | 2026-08-12 |
| An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) Veligrotug, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 188 | 2023-11-01 | 2026-08-13 |
| Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease, TED | Phase 3 | Completed | Hoffmann-La Roche | 131 | 2023-10-26 | 2026-07-31 |
| A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease IBI311 - Thyroid Eye Disease, TED | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 91 | 2023-10-20 | 2026-05-01 |
| A Study of IBI311 in Subjects With Active Thyroid Eye Disease IBI311, placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 115 | 2023-02-14 | 2024-02-08 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 86 | 2023-01-05 | 2026-04-01 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 114 | 2022-11-23 | 2025-12-03 |
| A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) Veligrotug, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 113 | 2022-11-16 | 2026-08-13 |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Completed | Sling Therapeutics, Inc. | 90 | 2022-07-01 | 2026-09-23 |
| Thyroxine Therapy for Recurrent Pregnancy Loss in Hypothyroid Women Levothyroxine Pill - Recurrent Early Pregnancy Loss, Thyroid Diseases | Phase 3 | Completed | Al-Kindy College of Medicine | 77 | 2022-03-01 | 2023-09-14 |
| Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease peri-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Assiut University | 92 | 2021-12-01 | 2023-11-14 |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients Placebo, Resmetirom - Non-Alcoholic Fatty Liver Disease | Phase 3 | Completed | Madrigal Pharmaceuticals, Inc. | 1343 | 2019-12-16 | 2023-09-05 |
| Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis Propylthiouracil, Methimazole - Hyperthyroidism, Graves Disease | Phase 3 | Completed | Universitas Indonesia | 36 | 2019-01-01 | 2021-11-12 |
| Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Teprotumumab - Thyroid Eye Disease | Phase 3 | Completed | Amgen | 51 | 2018-04-16 | 2024-06-28 |
Showing 20 of 55. Sign in to see all of them.
Graves Ophthalmopathy (20) · Thyroid Neoplasms (14) · Graves Disease (8) · Hypothyroidism (4) · Euthyroid Sick Syndromes (3) · Exophthalmos (3) · Hyperthyroidism (3) · Autoimmune Diseases (2) · Carcinoma, Medullary (2) · Dyslipidemias (2) · Heart Defects, Congenital (2) · Lymphatic Metastasis (2) · Thyroid Cancer, Papillary (2) · Thyroid Nodule (2)
Endocrine System Diseases (54) · Immune System Diseases (25) · Goiter (24) · Eye Diseases (23) · Hyperthyroidism (23) · Orbital Diseases (23) · Autoimmune Diseases (22) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22) · Exophthalmos (21) · Eye Diseases, Hereditary (20) · Genetic Diseases, Inborn (20) · Endocrine Gland Neoplasms (17) · Head and Neck Neoplasms (17) · Neoplasms (17)
Thyroxine (9) · Sodium Chloride (3) · Triiodothyronine (3) · Iodine-131 (2) · Methylprednisolone (2) · Propylthiouracil (2) · Thyrotropin Alfa (2) · satralizumab (2) · teprotumumab (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Bimatoprost (1) · Carbimazole (1) · Dental Occlusion (1) · Dexamethasone (1)
Viridian Therapeutics, Inc. (5) · Samsung Medical Center (4) · Genzyme, a Sanofi Company (3) · Amgen (2) · Cantonal Hospital of St. Gallen (2) · Hoffmann-La Roche (2) · Immunovant Sciences GmbH (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · National Cardiovascular Center Harapan Kita Hospital Indonesia (2) · AHS Cancer Control Alberta (1) · AdministrateurCIC (1) · Ain Shams University (1) · Al-Kindy College of Medicine (1) · Assistance Publique Hopitaux De Marseille (1) · Assiut University (1)
United States (21) · Germany (15) · France (13) · Italy (12) · Spain (12) · South Korea (11) · United Kingdom (11) · Canada (10) · Poland (10) · Australia (7) · Austria (7) · Belgium (5) · China (5) · Switzerland (5) · Brazil (4)
Thomas Clerici, MD (2) · Ahmed Abdelal, MD (1) · Alexander McEwan, MB, MSc, MD, FRCP (1) · Ana L Maia, MD, PhD (1) · Andreas Schuck, MD PhD (1) · Annamaria Colao (1) · Annie M Sawka, MD, PhD (1) · Brian Casey, MD (1) · Burkhard Riemann, MD PhD (1)
PMID 41066062, PMID 14652672, PMID 14668957, PMID 16400382, PMID 19322503, PMID 19850694, PMID 20505894, PMID 20632263, PMID 21834960, PMID 22025146, PMID 22753906, PMID 23009127, PMID 23984185, PMID 24002501, PMID 24015953, PMID 24768112, PMID 25343233, PMID 25563879, PMID 25671254, PMID 26074402, PMID 26088605, PMID 26195199, PMID 26370187, PMID 26426092, PMID 27548104, PMID 27797318, PMID 28237867, PMID 28249134, PMID 28562541, PMID 29045520, PMID 30471649, PMID 31540966, PMID 31558473, PMID 31971679, PMID 33172865, PMID 33611104, PMID 33637020, PMID 33768488, PMID 34851445, PMID 34856574, PMID 37786277, PMID 37845512, PMID 39355401, PMID 41066129, PMID 41142528, PMID 41953252, PMID 42492995
2017 (2), 2023 (2), 2005 (1), 2009 (1), R01DK077814 (1), U10HD021410 (1), U10HD027860 (1), U10HD027869 (1), U10HD027915 (1), U10HD027917 (1), U10HD034116 (1), U10HD034136 (1), U10HD034208 (1), U10HD036801 (1), U10HD040485 (1)